Diets Fade, Drugs Trade: Why GLP-1 Is the Hottest Ticker in Town
Weight loss may very well be humanity’s oldest obsession.
It has outlived empires, religions, and even entire civilisations.
The Greeks believed long walks in the sun and a diet of barley bread could melt away excess fat.
The Romans downed vinegar tonics with the conviction of a fine wine ritual.
In Victorian England, people swallowed live tapeworms hoping the parasites would do the heavy lifting while they kept eating pudding.
By the 1930s, grapefruit was the miracle cure.
By the 1980s, Jane Fonda’s neon leotards had living rooms bouncing in step aerobics marathons.
Absurd, dangerous, laughable and yet, constant. Because weight loss has never really been about health.
It has always been about status, aspiration and power.
The lengths people were, and are, willing to reveal something primal.
We’ve always been ready to barter safety, comfort, even dignity for control over our bodies.
The Endless Weight-Loss Obsession
Diet culture is a multi-billion-dollar industry.
Fad teas, keto hacks, “detox” juices, plastic surgeries—all part of the same machine.
But the latest chapter has boiled it down to three clinical-sounding letters: GLP-1.
Enter Serena Williams.
When one of the greatest athletes of all time casually name-drops drugs like Ozempic, it’s no longer just a doctor’s prescription.
Serena doesn’t just move crowds on the tennis court; she moves conversations.
And when products move from sterile clinics to Instagram reels, markets have a funny habit of moving too.
A Market on Steroids
GLP-1 drugs like semaglutide, the active ingredient in Ozempic, aren’t just trimming waistlines.
They’re inflating balance sheets.
In 2023, Ozempic pulled in a jaw-dropping $13.8 billion in the US alone, making it the best-selling drug.
Analysts expect the global market to balloon to $133 billion by 2030, powered by over 137 million eligible American users.
The ripple effects are already showing up in unexpected places.
Users are reportedly cutting food purchases by 11%, alcohol intake by 33%, and calories by nearly 30%.
Walmart flagged a decline in snack sales.
Airlines are experimenting with “wellness travel.”
Even fashion is quietly pivoting towards athleisure and body-positive lines.
For traders, that means pharma isn’t the only play.
FMCG, retail and travel stocks may see ripple effects too.
India’s Pharma Countdown
Novo Nordisk’s semaglutide patent expires in 2026.
That’s a countdown clock for local pharma majors.
Sun Pharma, with FY25 revenue of ₹51,602 crore, has already launched Leqselvi in the US and is doubling down on speciality drugs.
Dr. Reddy’s, at ₹31,229 crore revenue, is in the semaglutide generics race.
Cipla is prepping both domestic and export versions.
Biocon is elbow-deep in peptide Active Pharmaceutical Ingredients (APIs), with US FDA approval for Sitagliptin.
Glenmark even bagged early bragging rights with its generic liraglutide launch in 2024.
Policy & Pricing Tailwinds
The ₹15,000 crore PLI 2.0 scheme, running till FY 2027–28, is designed to back high-value pharma manufacturing.
Already, ₹3,215 crore has been disbursed to 45 companies, with incentive slabs starting at 10% of incremental sales.
For vertically integrated players like Sun and Cipla, that’s margin waiting to be unravelled.
Add the pricing angle: Ozempic’s monthly cost in the US has dropped from $997 to $499, widening access.
Indian generics will land even lower, letting domestic pharma play the volume game with margins that could fatten faster than the waistlines they’re meant to shrink.
The Story That Moves Markets
But here’s the cheeky truth.
Serena Williams hasn’t changed the science of GLP-1.
What she has changed is the story.
And stories, be it from ancient tapeworm pills to TikTok reels, are what move markets.
Once the narrative tilts, demand snowballs, supply chains strain, and valuations spike.
The world’s obsession with thinness has been constant, shifting from barley diet to worm pills to syringes of semaglutide.
But today, it isn’t just bodies being reshaped. It’s portfolios.
Because when celebrity, policy, and patents collide, the market usually listens.
Sometimes the smartest trade ideas don’t come from balance sheets or lab reports.
They come from the same place humans have always looked for shortcuts: vanity, celebrity, and the desperate hope for transformation.
For investors, the real weight-loss story isn’t happening on the scales.
It’s unfolding on the ticker.
Sources and References:
This article is for informational purposes only and does not constitute financial advice. It is not produced by the desk of the Kotak Securities Research Team, nor is it a report published by the Kotak Securities Research Team. The information presented is compiled from several secondary sources available on the internet and may change over time. Investors should conduct their own research and consult with financial professionals before making any investment decisions. The above images were generated using AI. Read the full disclaimer here.
Investments in securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed SEBI prescribed limit. The securities are quoted as an example and not as a recommendation. SEBI Registration No-INZ000200137 Member Id NSE-08081; BSE-673; MSE-1024, MCX-56285, NCDEX-1262.
